Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617171 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| SCHEMBL5171234 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| SCHEMBL9343685 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL15329139 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL5105833 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| Acetic Acid SCHEMBL11614488 | 0.94 | ALDH1A1 (0.51) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| SCHEMBL4339192 | 0.88 | CHRM2 (0.42) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 | |
| SCHEMBL4762996 | 0.88 | CHRM2 (0.42) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 | |
| SCHEMBL7493133 | 0.88 | CHRM2 (0.42) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 | |
| Acetonitrile SCHEMBL28099504 | 0.88 | CHRM2 (0.49) | ALDH1A1CHRNA7GAACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4408838-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023053007-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | KEMPHARM DENMARK A/S (DK) | 2023-04-06 | — | — | WO | disclosed |
| US-20180325878-A1 | N-BIARYLAMIDES | BAYER IP GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| EP-1487834-B1 | AZA-BICYCLIC N-BIARYLAMIDES WITH AFFINITY FOR THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR | BAYER HEALTHCARE AG (DE) | 2007-04-25 | — | — | EP | disclosed |
| EP-1487834-B1 | AZA-BICYCLIC N-BIARYLAMIDES WITH AFFINITY FOR THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR | BAYER HEALTHCARE AG (DE) | 2007-04-25 | — | — | EP | disclosed |
| EP-1651645-B1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1651645-B1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-7138410-B2 | Aza-bicyclic N-biarylamides with affinity for the α7 nicotinic acetylcholine receptor | BAYER HEALTHCARE AG (DE) | 2006-11-21 | — | — | US | disclosed |
| US-20050154045-A1 | Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor | BAYER HEALTHCARE AG (DE) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180325878-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | ALDH1A1 2433/4885CHRNA7 190/4885GAA 59/4885 |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | CHRNA7, CHRNA3, CHRNA5 | ALDH1A1 3160/4885CHRNA7 1/4885GAA 1619/4885 |
| US-20050154045-A1 | Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 1192/4885CHRNA7 1/4885GAA 744/4885 |
| US-20160310474-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | ALDH1A1 2433/4885CHRNA7 190/4885GAA 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.